Photo from wikipedia
Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid… Click to show full abstract
Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR‐CM). This study aimed to evaluate tolerability, clinical outcomes, and changes in NT‐proBNP levels and glomerular filtration rate (GFR) in ATTR‐CM patients treated with dapagliflozin.
Keywords:
amyloid cardiomyopathy;
inhibitor therapy;
transthyretin amyloid;
sglt2 inhibitor
Journal Title: ESC Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ESC Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!